Category: Clinical trials

Boehringer Ingelheim’s Investigational Biologic Cleared Skin Better than Ustekinumab in Head-to-Head Phase II Psoriasis Study

SAN FRANCISCO, Calif., March 20, 2015 – For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*. Nearly double the percentage of patients with moderate-to-severe plaque psoriasis achieved clear...

Biogen Idec Presents Positive Interim Results From Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab

CAMBRIDGE, Mass., Friday, March 20, 2015 – Today Biogen Idec (NASDAQ:BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an acceptable safety profile and...

New Data from Boehringer Ingelheim’s GLORIA<sup>TM</sup>-AF Registry Show Non-Valvular Atrial Fibrillation (NVAF) Patients at High Risk of Stroke May Be Undertreated

Ridgefield, CT, March 16, 2015 –Boehringer Ingelheim Pharmaceuticals, Inc. today will present results from two analyses of the GLORIATM-AF Registry Program examining the use of antithrombotic treatment to reduce the risk of stroke for patients...